Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
← catalyst calendarNCT07221344 · readout ≤ 315 d
Sponsored by Arrowhead Pharmaceuticals (industry) · ARWR — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
112estimated
Sites
3
Countries
Canada, New Zealand
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-18 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Alzheimer Disease
- Alzheimer Disease, Early Onset
Interventions
- Drug: ARO-MAPT-SC
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Treatment-Emergent Adverse Events (TEAEs) Over Time
measured Through End of Study (EOS), Day 270
Permalink · ARWR's whole pipeline · Catalyst calendar · Every registered study · What changed